Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384966 · ClinicalTrials.gov registry record · Phase 2
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
A Phase 2 study, sponsored by Viatris Innovation.
- Completed
- Registry status
- Phase 2
- Development phase
- 346
- Enrollment target
NCT03384966 is a Phase 2 study that has completed, run by Viatris Innovation. The registered enrollment target is 346 participants.
The verdict
NCT03384966, a Phase 2 study, has completed, sponsored by Viatris Innovation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 346 participants
- Enrollment target
Study Summary
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a difference if the drug is injected in the thigh or in the belly. This study will also help to find out more about the safety of this new drug.
Interventions
- DRUG Placebo
- DRUG Selatogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384966
The ClinicalTrials.gov registry entry for NCT03384966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viatris Innovation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03384966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03384966 about?
NCT03384966 is a clinical study titled "A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease". The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly. Another goal is to know how fast and for how long selatogrel (ACT-246475) works and if there is a ...
What is the current status of trial NCT03384966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2018-01-24. Estimated completion is 2018-09-18.
What interventions are being tested in trial NCT03384966?
The interventions under investigation include: Placebo (DRUG), Selatogrel (DRUG).
Who is sponsoring clinical trial NCT03384966?
This trial is sponsored by Viatris Innovation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.